0.4256

1.50% -0.0065

After Hours: .4148 -0.0108 -2.54%

Akili Inc (AKLI)

Overview News Price History Option Chain Financials Discussions Forecast

Akili Inc stock is currently priced at $0.4256, with a 24-hour trading volume of 164.59K. It has seen a -1.50% decreased in the last 24 hours and a +99.62% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.431 pivot point. If it approaches the $0.4221 support level, significant changes may occur.

Previous Close:

$0.4321

Open:

$0.4212

24h Volume:

164.59K

Market Cap:

$33.45M

Revenue:

$1.68M

Net Income/Loss:

$-59.49M

P/E Ratio:

3.4185

EPS:

0.1245

Net Cash Flow:

$-58.01M

1W Performance:

-0.37%

1M Performance:

+99.62%

6M Performance:

-5.78%

1Y Performance:

-69.60%

1D Range:

$0.42

$0.44

52W Range:

$0.1912

$1.67

Akili Inc Stock (AKLI) Company Profile

Name

Akili Inc

Sector

Healthcare (1209)

Industry

Health Information Services (65)

Phone

617 456 0597

Address

125 Broad Street, 5th Floor, Boston

Employee

109

Twitter

Next Earnings Date

Latest SEC Filings

AKLI's Discussions on Twitter

Akili Inc Stock (AKLI) Latest News

Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of ... - The Globe and Mail

The Globe and Mail

AKLI Stock Earnings: Akili Beats EPS, Misses Revenue for Q1 2024 - InvestorPlace

InvestorPlace

Akili Reports First Quarter 2024 Financial Results and Provides Business Update - Business Wire

Business Wire

Akili (NASDAQ:AKLI) Stock Price Down 0.5% - Defense World

Defense World

Akili, Inc. (NASDAQ:AKLI) Short Interest Update - Defense World

Defense World

Therapeutic video game maker Akili lays off workers for third time in 16 months - The Business Journals

The Business Journals

Akili Inc Stock (AKLI) Financials Data

Akili Inc (AKLI) Revenue 2024

AKLI reported a revenue (TTM) of $1.68 million for the quarter ending December 31, 2023, a +419.50% rise year-over-year.

Akili Inc (AKLI) Net Income 2024

AKLI net income (TTM) was -$59.49 million for the quarter ending December 31, 2023, a -647.02% decrease year-over-year.

Akili Inc (AKLI) Cash Flow 2024

AKLI recorded a free cash flow (TTM) of -$58.01 million for the quarter ending December 31, 2023, a +30.58% increase year-over-year.

Akili Inc (AKLI) Earnings per Share 2024

AKLI earnings per share (TTM) was -$0.7623 for the quarter ending December 31, 2023, a -456.42% decline year-over-year.

Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive dysfunction. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It offers selective stimulus management engine design to target neutral system, such as focus, interference processing, and multitasking; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company is headquartered in Boston, Massachusetts.